目的:评估单操作孔达芬奇机器人胸腔镜肺叶切除术的近期疗效。方法:收集2022.06~2023.08以来于烟台毓璜顶医院胸外科行达芬奇机器人胸腔镜肺叶切除术手术的肺癌患者临床资料共150例,其中81例采用传统四孔达芬奇机器人胸腔镜肺叶切除术...目的:评估单操作孔达芬奇机器人胸腔镜肺叶切除术的近期疗效。方法:收集2022.06~2023.08以来于烟台毓璜顶医院胸外科行达芬奇机器人胸腔镜肺叶切除术手术的肺癌患者临床资料共150例,其中81例采用传统四孔达芬奇机器人胸腔镜肺叶切除术为对照组,69例采用单操作孔达芬奇机器人胸腔镜肺叶切除术为观察组,比较两组近期疗效。结果:观察组术中出血量为24.20 ± 20.68 ml小于对照组的31.11 ± 19.35 ml,P 0.05,差异均无统计学意义。结论:达芬奇机器人单操作孔胸腔镜下肺叶切除术具有与传统四孔机器人辅助胸腔镜下肺叶切除术同样的疗效和安全性,术中创伤更小,术后短期生活质量更高,值得临床推广。Objective: Evaluate the short-term efficacy of two-port Da Vinci robot thoracoscopic lobectomy. Methods: Collect 150 patients with lung cancer who underwent Da Vinci robotic thoracoscopic lobectomy in the Department of thoracic surgery of Yantai Yuhuangding Hospital from June 2022 to August 2023. Among them, 81 patients underwent four-hole Da Vinci robotic thoracoscopic lobectomy as the control group, and 69 patients underwent two-port Da Vinci robotic thoracoscopic lobectomy as the observation group. Compare the short-term efficacy of the two groups. Result: The intraoperative blood loss in the observation group was 24.20 ± 20.68 ml, less than 31.11 ± 19.35 ml in the control group, P < 0.05;The visual analogue scale score of the observation group on the first day after operation was 3.84 ± 1.01 points, less than 5.48 ± 0.85 points of the control group, P < 0.05. No perioperative mortality occurred in either group. Conclusion: Da Vinci robot two-port video-assisted thoracoscopic lobectomy has the same efficacy and safety as traditional four-port robot-assisted thoracoscopic lobectomy, with less intraoperative trauma and higher short-term postoperative quality of life, which is worthy of clinical promotion.展开更多
文摘目的:评估单操作孔达芬奇机器人胸腔镜肺叶切除术的近期疗效。方法:收集2022.06~2023.08以来于烟台毓璜顶医院胸外科行达芬奇机器人胸腔镜肺叶切除术手术的肺癌患者临床资料共150例,其中81例采用传统四孔达芬奇机器人胸腔镜肺叶切除术为对照组,69例采用单操作孔达芬奇机器人胸腔镜肺叶切除术为观察组,比较两组近期疗效。结果:观察组术中出血量为24.20 ± 20.68 ml小于对照组的31.11 ± 19.35 ml,P 0.05,差异均无统计学意义。结论:达芬奇机器人单操作孔胸腔镜下肺叶切除术具有与传统四孔机器人辅助胸腔镜下肺叶切除术同样的疗效和安全性,术中创伤更小,术后短期生活质量更高,值得临床推广。Objective: Evaluate the short-term efficacy of two-port Da Vinci robot thoracoscopic lobectomy. Methods: Collect 150 patients with lung cancer who underwent Da Vinci robotic thoracoscopic lobectomy in the Department of thoracic surgery of Yantai Yuhuangding Hospital from June 2022 to August 2023. Among them, 81 patients underwent four-hole Da Vinci robotic thoracoscopic lobectomy as the control group, and 69 patients underwent two-port Da Vinci robotic thoracoscopic lobectomy as the observation group. Compare the short-term efficacy of the two groups. Result: The intraoperative blood loss in the observation group was 24.20 ± 20.68 ml, less than 31.11 ± 19.35 ml in the control group, P < 0.05;The visual analogue scale score of the observation group on the first day after operation was 3.84 ± 1.01 points, less than 5.48 ± 0.85 points of the control group, P < 0.05. No perioperative mortality occurred in either group. Conclusion: Da Vinci robot two-port video-assisted thoracoscopic lobectomy has the same efficacy and safety as traditional four-port robot-assisted thoracoscopic lobectomy, with less intraoperative trauma and higher short-term postoperative quality of life, which is worthy of clinical promotion.
